Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements

Exploring the Influence of GLP-1 Medications on External Food Cue Reactivity and Resultant Food Choice and Intake

The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?

Participants will:

• report daily food consumption for a total of 10 days,
• receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days,
• answer several questionnaires,
• and complete two in-person visits to complete a virtual reality food selection task.

Inclusion Criteria:

• Adults (18+) with overweight or obesity (BMI >25 kg/m2)
• On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
• Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
• Fluent in English

Exclusion Criteria:

• Do not have consistent access to a smart phone that can access the study software
• Diagnosed with cognitive or physical disability or epilepsy
• Adults taking a compound GLP-1